ENDRA Life Sciences (NDRA) Free Cash Flow (2016 - 2026)

ENDRA Life Sciences (NDRA) has 11 years of Free Cash Flow data on file, last reported at -$1.1 million in Q1 2026.

• Free Cash Flow for Q1 2026 came in at -$1.1 million, up 14.56% year-over-year; the trailing twelve-month figure through Mar 2026 was -$5.0 million (up 23.59% YoY), and the FY2025 annual result was -$5.2 million, up 29.89% from the prior year.
• Free Cash Flow grew to -$1.1 million in Q1 2026 per NDRA's latest filing, from -$1.6 million in the prior quarter.
• Over five years, Free Cash Flow peaked at -$1.1 million in Q2 2025 and troughed at -$3.4 million in Q2 2022.
• A 5-year average of -$2.1 million and a median of -$2.2 million in 2024 frame the typical range for Free Cash Flow.
• The sharpest annual moves came in 2022 and 2025: Free Cash Flow decreased 21.27% in 2022, then surged 46.26% in 2025.
• A 5-year view of Free Cash Flow shows it stood at -$3.1 million in 2022, then jumped by 30.24% to -$2.2 million in 2023, then jumped by 30.52% to -$1.5 million in 2024, then retreated by 6.33% to -$1.6 million in 2025, then jumped by 30.53% to -$1.1 million in 2026.
• Business Quant data shows NDRA's Free Cash Flow at -$1.1 million in Q1 2026, -$1.6 million in Q4 2025, and -$1.2 million in Q3 2025.